Eosinophils vs Mast Cells: What's the Difference, and When Do They Overlap?
Eosinophils and mast cells are different cells with different jobs. What a biopsy or blood result showing eosinophils means, and where the two overlap.
Photo: Teslariu Mihai / Unsplash
Eosinophils vs Mast Cells: What's the Difference, and When Do They Overlap?
Eosinophils and mast cells are two different white blood cells, and finding one on a test doesn't mean you have a condition involving the other. Eosinophils get recruited into tissue over hours and days. Mast cells already live in the tissue and can release histamine within seconds. Both show up in gut biopsies. So when a pathologist counts eosinophils in your colon, that's a finding about one cell type. It isn't a mast cell diagnosis.
Two cells, two jobs
Both start in your bone marrow. That's roughly where the similarity stops.
Eosinophils finish developing in the marrow and travel through your blood. Two signals then decide where they end up. IL-5 expands the eosinophil population, and a set of homing signals called eotaxins pulls them into tissue. Their granules carry proteins that are toxic to parasites, and to your own tissue when they get released into it.
Mast cells run on a different clock. They leave the marrow immature, finish maturing inside the tissue they'll live in, and stay there. You'll find them stationed wherever your body meets the outside world, your gut lining included. They come pre-loaded with histamine and with tryptase, an enzyme mast cells dump when they fire. So when something triggers a mast cell, the response is immediate.
Mast cells are the alarm that goes off in seconds. Eosinophils are the crew that arrives over the following hours and days.
Your colon is supposed to have eosinophils in it
Eosinophils are normal residents of the gut lining. They live there in healthy people, doing maintenance work in the lining, along the whole digestive tract except the esophagus.
How many is too many?
The answer depends partly on geography. A 1997 review of 256 normal descending and sigmoid colon biopsies, collected from pathology departments in several parts of the United States, found the average eosinophil count was highest in the South. Between the New Orleans mean and the Boston mean there was a 35-fold difference. Thirty-five times as many, in tissue everyone agreed was normal. Nobody knows why. Environmental and dietary allergens are the usual suspects. It's an old paper and not a modern reference range. Still, a count that reads high in Boston can be ordinary in Louisiana.
A 2021 allergy and immunology work group report said the same about both cell types. Thresholds are settled for a couple of conditions and disputed for the rest, and that inconsistency can delay someone's correct diagnosis.
What an eosinophilic finding usually prompts
The esophagus is the exception with a settled number. Eosinophilic esophagitis, or EoE, is a chronic allergic inflammation of the swallowing tube, and it's diagnosed at 15 or more eosinophils per high-power field, one field of view under a microscope at high magnification. A healthy esophagus has none at all, so even a few stands out.
Further down, in the stomach and intestines, the picture is looser. Those conditions only recently got a shared naming system, and researchers are still working out how they differ.
On the blood side, a raised eosinophil count has a long list of ordinary explanations: allergy, parasitic infection, drug reactions, sometimes a blood disorder. A 2012 international consensus even named the case where the count stays high and no cause turns up: hypereosinophilia of undetermined significance. A number nobody can explain yet is its own recognized category.
Where the two cells overlap
In allergic tissue, mast cells and eosinophils are usually found next to each other, and researchers describe them as a functional pair, an "allergic effector unit," trading signals through the chemicals they release, called mediators, and through direct contact. Each one amplifies the other.
EoE shows this well. The condition is named for eosinophils and diagnosed by counting them, but the same esophagus also carries a marked increase in mast cells. A 2024 study mapped mast cells across whole esophageal biopsies with machine learning. In active EoE, mast cells rose in the surface layer and fell in the lamina propria, the connective tissue layer underneath the lining. Mast cell density tracked how much eosinophilic inflammation and scarring were present.
They also lean on each other. Children with EoE in one study were given an antibody aimed squarely at eosinophils, and their esophageal mast cells dropped too. Forty-three biopsy specimens had enough tissue for a paired before-and-after comparison, and in 77 percent of those pairs the mast cell count came down. Among the ones who responded, mast cells in that surface layer fell from 62 per high-power field to 19. The two cell types were physically paired before treatment, and eosinophils turned out to be a major source of IL-9, a growth factor mast cells need.
That tells you the two populations are linked. The drugs involved are prescription biologics, meaning medicines made from living cells, and their approved uses are narrow.
What to bring back to the doctor who ordered the test
Start with the report itself. Which segment was sampled, what the count was, and what range that lab uses.
If mast cells are your actual question, they need their own stain. A standard slide doesn't show them well. A pathologist has to stain specifically for tryptase, and that isn't part of a routine biopsy.
Consensus 1 and Consensus 2, and why the difference matters to your biopsy
A tissue count can't settle a mast cell diagnosis by itself, and part of the reason is that there isn't one definition to settle it against. Mast cell activation syndrome, or MCAS, a condition where mast cells release their contents inappropriately, has two sets of criteria in circulation. Clinicians call them Consensus 1 and Consensus 2.
Consensus 1 is the set most major associations follow, and it asks for three things at once.
The first is symptoms. They have to come in episodes, and they have to involve two or more body systems. In practice that means things like chronic hives, itching or flushing on the skin, constant nasal congestion or a cough that never settles, reflux and cramping and bloating and diarrhea in the gut, low blood pressure with fainting or near-fainting, headaches, a racing heart, or repeated unexplained anaphylaxis.
The second is laboratory evidence that a mast cell mediator went up during a flare. The classic version is tryptase measured twice: a baseline drawn between flares, and a second draw during a flare that comes back at least 20 percent above that baseline plus another 2 ng/mL on top. A 24-hour urine collection can also count if it shows a rise in N-methylhistamine, prostaglandin D2, 11-beta-prostaglandin F2-alpha or leukotriene E4, and so can a plasma histamine or one of its metabolites.
The third is response. Symptoms have to improve on medication aimed at mast cells, usually over about two to four weeks.
The criticism of Consensus 1 is that it's too strict. The flare tryptase has to be drawn during the flare, which is hard to arrange when appointments book out months ahead. The urine collections are cumbersome. Several markers break down fast enough that timing decides the result. People with obvious mast cell trouble fail to meet the threshold routinely.
Consensus 2, published in 2020 by Afrin, Molderings and a large group of co-authors, keeps the same major requirement, episodic symptoms in two or more organ systems, and then lets a list of minor criteria carry the rest. It doesn't hinge on catching an elevated tryptase. Response to mast-cell-directed treatment is itself one of the minor criteria, which means a documented trial and a documented improvement can be part of how the diagnosis gets made rather than something that happens after. Tissue findings, including increased or clustered mast cells on a biopsy, sit on that same list.
The criticism of Consensus 2 is the mirror image. Wider criteria let more people in, which helps patients reach treatment, and they also produce a more varied diagnosed population, which makes research on that population harder to interpret.
Both criticisms are fair, and that's why the specialists haven't settled on one set. What it means for your report is practical. Under Consensus 1, your biopsy is background and the mediator number is the thing. Under Consensus 2, that same biopsy can be one of the pieces that completes the picture. The same argument runs in skin, where rosacea tissue holds more mast cells without adding up to MCAS. So it's a fair question to ask your clinician outright: which set are you working from?
One more sorting question I use with patients. Is this a faucet problem or a drain problem? If cell counts come back clearly elevated, that points toward overproduction, the faucet running hard. If counts keep reading normal while symptoms continue, the question moves to clearance, which is the territory of histamine intolerance and whether the drain is keeping up. Those two get worked up differently, and a biopsy is one of the few things that tells them apart.
Remember that all of this is what these findings generally mean. Your own case may carry nuances that a general explanation can't reach, so bring this to your health care team as something to talk through with them, rather than something to run off with on your own.
If MCAS is the question you keep circling back to, MCAS: What You Need to Know First sets out what the criteria actually require, and where to start when a biopsy hasn't settled it.
FAQ
Do eosinophils on a biopsy mean I have MCAS?
No. Eosinophils and mast cells are separate cell types, and a count of one says nothing directly about the other. The stricter of the two MCAS definitions, called Consensus 1, asks for episodic symptoms across more than one body system, a measured rise in one of the chemicals mast cells release during an episode, and improvement on mast-cell-directed treatment. Counting mast cells also takes a separate stain that a routine biopsy doesn't include.
What is the difference between Consensus 1 and Consensus 2 criteria for MCAS?
Both start from the same requirement: episodic symptoms affecting two or more organ systems. Consensus 1, which most major associations follow, then requires laboratory evidence of a mast cell mediator rising during a flare, plus improvement on mast-cell-directed treatment. Consensus 2, published in 2020 by Afrin, Molderings and colleagues, keeps the symptom requirement but lets a list of minor criteria carry the rest, so it does not hinge on catching an elevated tryptase. Response to mast-cell-directed treatment is one of those minor criteria, and tissue findings like increased or clustered mast cells on biopsy are another.
What is eosinophilic esophagitis?
Eosinophilic esophagitis, or EoE, is chronic allergic inflammation of the esophagus, the tube between your throat and your stomach. It's diagnosed when a biopsy shows 15 or more eosinophils per high-power field, which is one view under a microscope at high magnification. A healthy esophagus normally has no eosinophils in it at all, so the finding stands out there in a way it doesn't in the colon.
Can you have an eosinophilic condition and mast cell activation at the same time?
Yes, and the two cells are known to interact. In allergic tissue they are usually found next to each other and trade signals back and forth. Esophageal biopsies in active EoE show increased mast cells alongside the eosinophils, so having features of both is a recognized pattern rather than a contradiction.
Why are there eosinophils in my colon if I'm healthy?
Eosinophils are normal residents of the gut lining everywhere except the esophagus. They live in the mucosa, the moist inner lining of the gut, in healthy people as part of ordinary immune housekeeping. What counts as too many varies by segment, by lab, and even by region, which is why the number on your report needs interpreting against the range that lab uses.
Can an old biopsy be tested for mast cells?
Sometimes. Labs often keep tissue blocks from a previous endoscopy or colonoscopy for years, and a mast cell stain can be run on stored tissue without a new procedure. Retention policies vary by lab and by state, so the question to ask your provider is whether your specific block is still available.
References
- 1.
- 2.
- 3.
- 4.
- 5.
- 6.
- 7.
- 8.
- 9.
- 10.
- 11.
- 12.
- 13.ClinicalKnieff J. Clinical practice note: re-staining stored gastrointestinal biopsy blocks for mast cells, and the two competing criteria sets patients encounter. 2026.
